← All trials
NCT05737030
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 6, 2023
- Primary completion
- Feb 29, 2024
- Completion date
- Jan 31, 2025
- First posted
- Feb 21, 2023
- Last posted
- Mar 28, 2023
- Enrollment
- 55
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Medical University of GrazLead sponsor
- Medical University of GrazReponsible party - principal investigator
- CBmed Ges.m.b.H.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.